PACS GROUP INC (PACS)
Health Care · skilled nursing and long-term care facilities · NYSE
PACS Group operates an extensive network of post-acute healthcare facilities, delivering skilled nursing and rehabilitative services across the United States.
What PACS GROUP INC does
PACS Group is a holding company that operates a network of post-acute healthcare facilities, primarily skilled nursing facilities (SNFs) and assisted living facilities. The company provides a range of healthcare services, including skilled nursing, physical, occupational, and speech therapy, and hospice and home health services to patients and residents.
Themes: post-acute care, skilled nursing facilities, senior living, rehabilitative services, healthcare facility operations
Fundamentals
- Price$47.72 as of 2026-10-20 close
- Market cap$7.6B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return+276.3% 2025-10-20 close $12.68 → 2026-10-20 close $47.72
- P/E27.91 as of 2026-10-20
- Net margin+3.6% FY2025, SEC XBRL
- ROE+20.1% FY2025, SEC XBRL
- ROIC+22.9% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31)
- Debt / equity0.22 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+29.3% FY2025, SEC XBRL
- Revenue CAGR (3y)+29.7% SEC XBRL
- Beta0.78 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
How PACS compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PACS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
67.3 #62 of 1,265 scored · #10 of 146 in Health Care
Growth 89th (3-year revenue CAGR 29.7%, revenue growth year over year 29.3%) and trend 89th (over the past 12 months this stock beat the market by 261.8 percentage points); weakest is capital return (27th, net share count bought back over the year -5.5, consecutive years of dividend increases 1 year).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which PACS reported a dividend payment is FY2024, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2024 ratio would not describe PACS today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2024) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $1.4B | $109M | $76M | $0.47 | $136M† |
| Q1 FY2026 2026-03-31 | $1.4B | $120M | $81M | $0.50 | $236M |
| Q4 FY2025 2025-12-31 | $1.4B† | $95M† | $60M† | $0.42† | -$3M† |
| Q3 FY2025 2025-09-30 | $1.3B | $86M | $52M | $0.32 | $205M† |
| Q2 FY2025 2025-06-30 | $1.3B | $80M | $51M | $0.31 | $53M† |
| Q1 FY2025 2025-03-31 | $1.3B | $48M | $28M | $0.17 | $150M |
| Q4 FY2024 2024-12-31 | $1.2B† | $72M† | $37M† | $0.25† | $65M† |
| Q3 FY2024 2024-09-30 | $1.0B | $23M | $16M | $0.10 | $209M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$164M
- Total debt$246M borrowings only; leases excluded
- Net debt$82M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How PACS GROUP INC looks technically
PACS GROUP INC (PACS) is trading 20.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 252 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 3.6% below its all-time high.
Trend
7
| Distance from the 200-day | it is trading 20.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +20.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $43.60 | $43.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $39.50 | $39.50 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 19 calendar days ago — the swings before that are what the structure reading is measured on | 19 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 252 trading days ago — a "golden cross", a bullish long-term signal | 252 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 65.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($40.55 to $48.16) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.49 | $49.49 |
|---|---|---|
| From the 52-week high | it is 3.6% below its 52-week high (its highest price of the past year) | -3.6% |
| Above the 52-week low | it is 362.9% above its 52-week low (its lowest price of the past year) | +362.9% |
| Below the 52-week high | it is 3.6% below its highest point of the past year | 3.6% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $49.49 (set on 2026-08-06) | $49.49 |
| Given back of the 52-week move | over the past year its closes ranged ($10.58 to $48.45), and it has given back essentially none of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $23.83 to $25.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.9% |
| From the all-time high | it is 3.6% below its all-time high | -3.6% |
| Nearest price level | it is trading 4.1% above a support level at $45.78 — a price it turned at three times since 2026-07-06, most recently on 2026-09-11. Since 2024-10-21 it has 19 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.1% |
| All-time low | its lowest closing price on record is $7.50 (set on 2025-09-09) | $7.50 |
| Above the all-time low | it is 536.3% above its all-time low | +536.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 65th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.65 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.65 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $39.49 and $47.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $39.49 – $43.61 – $47.73 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 5.0 daily ranges above its 200-day average price (20.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.02× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.3% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-09-02 has been "filled" 32 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 32 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.3 percentage points (the stock gained 13.3% while the market gained 1.0%) | +12.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.1 percentage points (the stock gained 6.7% while the market gained 3.6%) | +3.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 24.0 percentage points (the stock gained 32.6% while the market gained 8.5%) | +24.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 261.8 percentage points (the stock gained 276.3% while the market gained 14.6%) | +261.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.9% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.7% of the share price, which is taken to mean a barrier that gives way easily. | +6.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $39.70 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | +20.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $44.03 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +8.4% |
Price levels it has turned at before
PACS last closed at $47.72 on 2026-10-20. Since 2024-10-21 it has turned at 19 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $45.78 | Support | 4.1% below the last close | turned there three times · 2026-07-06 to 2026-09-11 |
| $43.93 | Support | 7.9% below the last close | turned there twice · 2024-11-01 to 2026-07-23 |
| $43.10 | Support | 9.7% below the last close | turned there three times · 2026-01-13 to 2026-09-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · in a strong, established uptrend (ADX) · Near the all-time high · beating the market · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$59.00 range $57.00 – $62.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PACS
- Consensus EPS estimate$0.5829 next reporting period, as of 2026-10-18
- Estimate change, 30 days-$0.01463 (-2.4%) from $0.5975, on 2026-09-13, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependence on third-party payor reimbursements (Medicare/Medicaid).","Significant regulatory and audit risks regarding care delivery and billing compliance.","Operational challenges related to labor shortages, recruitment of skilled personnel, and potential material weaknesses in internal financial controls."]
What changed in the latest 10-Q
AI-assisted comparison of PACS's 10-Q filed 2026-05-11 against the prior one filed 2025-11-19.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Annual Report for year ended December 31, 2025 (newer filing) vs. December 31, 2024 (older filing)
- Portfolio as of March 31, 2026 with 323 facilities serving over 31,900 patients daily (newer) vs. September 30, 2025 with 320 facilities serving over 31,100 patients daily (older)
- Operating model described as 'locally led, centrally supported' (newer) vs. 'decentralized, local' (older)
- Mature facilities defined as 'purchased greater than 36 months prior to the measurement date' (newer addition of specific definition)
- New facilities QM Star rating of 3.6 and occupancy rate of 83% as of March 31, 2026 (newer)
- Mature facilities QM Star rating of 4.4 as of March 31, 2026 (newer)
- SNF industry data showing decline to 'approximately 14,740 in 2025' (newer)
- Removed:
- Reference that Mature facilities metrics comparison was stated 'of 4.3 and 95%, respectively, as of September 30, 2025' (removed in newer)
- Statement that New facilities had 'average QM Star rating and occupancy rate... was 3.3 and 81%, respectively' as of September 30, 2025 (replaced with newer metrics)
- Language stating 'due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities' (removed in newer)
- Reference to SNF decline to 'approximately 14,800 in 2024' (updated to 2025 figure in newer)
- Language about 'the industry's stringent regulatory compliance obligations and with quality standards' (simplified to just 'quality standards' in newer)
- References to barriers to entry including Certificate of Need and regulatory requirements (removed in newer text as it appears truncated)
- Reworded:
- Operating model terminology changed from 'decentralized, local operating model' to 'locally led, centrally supported operating model'
- Changed from 'Mature facilities of 4.3 and 95%, respectively, as of September 30, 2025' to separate statement with comparison date of March 31, 2026 showing 4.4 rating
- Changed phrasing regarding SNF decline factors from 'inability of many facilities to comply with the industry's stringent regulatory compliance obligations and with quality standards' to 'inability of many facilities to comply with quality standards'
- Changed from 'a lack of technology and sophistication' to 'a lack of technology and sophistication' (substantively same but context shifted)
- Notes:
- Older filing text appears truncated at end of 'Growing Demand' section; newer filing also appears truncated at same section
- Comparison covers only the visible portions of MD&A; both texts cut off mid-sentence in final industry trends section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 47 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 14 sells ($12M) — 2 selling insiders
- Last 90 days · read to 2026-10-160 buys · 47 sells ($52M) — 4 selling insiders
- Last 180 days · read to 2026-10-160 buys · 74 sells ($86M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-16. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PACS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding PACS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 12,936,212
- Reported value $551,600,076
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PACS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PACS had 4,136,054 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
PACS had 2.61% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.94 days to cover at the same settlement.
- Reported short interest (shares) 4,136,054
- Short interest (% of shares outstanding) 2.61%
- Prior settlement (shares) 3,740,748
- Reported change 10.57%
- Days to cover (reported) 4.94
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- The Ensign Group (ENSG)
- Genesis Healthcare
- LifePoint Health
- Brookdale Senior Living (BKD)
- SavaSeniorCare
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PACS vs…
PACS ranks in…
Frequently asked questions
What does PACS GROUP INC (PACS) do?
PACS Group is a holding company that operates a network of post-acute healthcare facilities, primarily skilled nursing facilities (SNFs) and assisted living facilities. The company provides a range of healthcare services, including skilled nursing, physical, occupational, and speech therapy, and hospice and home health services to patients and residents.
What sector is PACS GROUP INC (PACS) in?
PACS GROUP INC (PACS) is classified in the Health Care sector. Its industry is skilled nursing and long-term care facilities. It trades on NYSE.
Who are PACS GROUP INC's (PACS) competitors?
Notable peers of PACS GROUP INC (PACS) include The Ensign Group, Genesis Healthcare, LifePoint Health, Brookdale Senior Living and SavaSeniorCare. This peer set is informational only — not financial advice.
Is PACS GROUP INC (PACS) overbought or oversold right now?
PACS GROUP INC (PACS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PACS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.